Key Takeaways:
Pfizer Inc. said the FDA granted priority review to its Talzenna (talazoparib) plus Xtandi (enzalutamide) combination for men with HRR gene-mutated metastatic castration-sensitive prostate cancer, setting a PDUFA action date in the final quarter of 2026.
"Intervening during the hormone-sensitive stage represents an important opportunity to delay progression before the disease becomes more difficult to manage," Jeff Legos, chief oncology officer at Pfizer, said in a statement.
The supplemental application is backed by the Phase 3 TALAPRO-3 trial, which enrolled 599 patients and showed the combination reduced the risk of radiographic progression or death by 52% versus placebo plus Xtandi. The benefit was consistent across patients with BRCA and non-BRCA HRR gene alterations, according to results presented at the 2026 American Society of Clinical Oncology annual meeting and published simultaneously in the New England Journal of Medicine. The safety profile matched the known profiles of each agent, with no new safety signals identified.
An expanded approval would allow Pfizer to move the combination into an earlier disease stage. The drug pair is currently approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer, a later-stage indication, and is authorized in more than 60 countries for that use. Metastatic castration-sensitive prostate cancer accounts for 5% to 10% of newly diagnosed cases, and up to 30% of those patients harbor HRR gene alterations, according to Pfizer. The combination is also under review by the European Medicines Agency for the same indication.
The priority review designation shortens the FDA's standard 10-month review to about six months, accelerating a potential label expansion that could broaden the addressable patient population for Talzenna. Pfizer did not disclose a peak sales estimate for the expanded indication. Investors will watch the PDUFA date in the fourth quarter for the final regulatory decision.
This article is for informational purposes only and does not constitute investment advice.
